Particle Data Platform
Diabetes Nerd

T1D Scientist Explains Why Curing 12 Patients Isn't Enough

7/9/202656 min

Send us Fan Mail

What would a cure for type 1 diabetes (T1D) actually look like, and when might it be available? These are pressing questions within the diabetes community following recent Eledon trial news. People are beginning to be cured. But when will this become a reality for the many?

In this special two-part episode, Dan Heller, a highly knowledgeable scientist who has been living with T1D even longer than I have, explains everything. Grab your coffee, settle in, and turn up the volume—you won't want to miss a word he shares!

Thanks for tuning in! Join the Diabetes Nerd Network.

Thanks to Eversense for sponsoring the Diabetes Nerd Podcast. Eversense is home to the world's only 365-Day CGM. See if it's right for you at eversensecgm.com/ginger.

DISCLAIMER: This video is not medical advice. Ginger Vieira is not a doctor. Please consult your healthcare team before making any changes to your healthcare regimen.

FIND MORE FROM GINGER VIEIRA

GINGER's DIABETES BOOKS

GINGER’S FAVE DIABETES-FRIENDLY PRODUCTS

SUPPORT INDEPENDENT DIABETES EDUCATION

👉 If you found value in today's episode and want to support independent diabetes education, advocacy, and storytelling, you can leave a tip at buymeacoffee.com/diabetesnerd. 

Every contribution helps keep the podcast going and allows us to continue bringing important conversations to the diabetes community. 

Thank you for being here. 🧡

DISCLOSURE: Ginger is an affiliate of Glow Gummies and Good Journey Donuts. By using her links to purchase, she may receive a small commission at no extra cost to you. Enjoy!

Clips

Reality-Check: 9-13 Year Timeline
Monotherapy Hype Debunked
Donor Math Doesn’t Add Up
Self-Stem Cells As Cure

Transcript preview

First 90 seconds

  1. Ginger Vieira· Host0:00

    Welcome back to the Diabetes Nerd podcast. This is part two of my interview with Dan Heller. Definitely listen to part one if you haven't already, because we reference a lot of the science he explained in part one of his interview. In this part of his interview, we're digging into how the FDA approval process for any new therapy really works, and what we still need to see with Eladon's therapy, Tegoprubart, before it's something that's actually brought to the market. Whether we're showing up at the hospital every 21 days for an infusion, or we're taking it as an injection at home, there's a lot of work still left to be done. So here we go, back to Dan. What do you make of the, and you might be addressing this soon, what do you make of the line, "It will soon be known..." There's two, two ways I've been told this. "It will soon be known that Tegoprubart can work as a monotherapy." Or also the line, you know, "We plan to make this a subcutaneous injection you can take at home."

  2. Dan Heller· Guest1:10

    Yeah.

  3. Ginger Vieira· Host1:10

    And because people are- I- Let me add, let me add- Yeah.

  4. Dan Heller· Guest1:14

    I, I- People hear this. Yeah.

  5. Ginger Vieira· Host1:16

    And what a lot of people are expecting, based on the hype and the influencer media about Eladon's trial with 12 participants, is that this is just kind

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click "Accept All" to consent, or "Decline non-essential" to opt out of non-essential cookies. Read our Privacy Policy.